Brain Neurorehabil.  2012 Mar;5(1):43-46. 10.12786/bn.2012.5.1.43.

A Case of Hyponatremia Associated with Paroxetine: A case report

• Sohn MK
• Hwang SL
• Song HT
• Lim JH

• KMID: 1965898
• DOI: http://doi.org/10.12786/bn.2012.5.1.43

Abstract

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) widely used for depression in brain damaged patients as it is known for its few affects on cognition or psychomotor function. Major side effects observed for paroxetine are vertigo, headache and tremor. It is reported that hyponatremia is also rarely observed. In 69 year-old male with left hemiplegia due to cerebral infarction had started taking 20 mg/day of paroxetine for depression. Next day the patient showed severe generalized weakness and decreased consciousness. Laboratory tests showed that serum sodium level was decreased to 102 mEq/L. Paroxetine administration was stopped and 3% sodium and oral furosemide were administered under the diagnosis of syndrome of inappropriate secretion of antidiuretic hormone (SIADH). We report a case of patient with severe hyponatremia due to SIADH within 2 days after use of paroxetine. This case emphasizes the need to monitor serum sodium level routinely at the initial treatment to prevent hyponatremia.

Keyword

hyponatremia; paroxetine; SIADH

MeSH Terms

Brain
Cerebral Infarction
Cognition
Consciousness
Depression
Furosemide
Headache
Hemiplegia
Humans
Hyponatremia
Inappropriate ADH Syndrome
Male
Organothiophosphorus Compounds
Paroxetine
Serotonin
Sodium
Tremor
Vertigo
Furosemide
Organothiophosphorus Compounds
Paroxetine
Serotonin
Sodium

Figure

• 

  Fig. 1 Axial DWI image shows focal cerebral infarction in right precentral gyrus.

• 

  Fig. 2 Changes of serum sodium level after paroxetine medication.

Reference

1. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: A systematic review of observational studies. Stroke. 2005. 36:1330–1340.

2. Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke. 2001. 32:113–117.

3. Harvey RL, Roth EJ, Yu D. Braddom RL, editor. Rehabilitation in Stroke Syndromes. Physical medicine and rehabilitation. 2007. 3rd ed. Philadelphia: Saunders;1195–1196.

4. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke. 2005. 36:1098–1103.

5. Masand PS, Narasimhan M, Patkar A. Paroxetine for somatic pain associated with physical illness: a review. Prim Care Companion J Clin Psychiatry. 2006. 8:122–130.

6. Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol. 1999. 47:211–217.

7. Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Corey SE, Begley AE, Bensasi SG, Weber E, Dew MA, Reynolds CF III, Pollock BG. Paroxetine-induced hyponatremia in older adults: A 12-Week Prospective Study. Arch Intern Med. 2004. 164:327–332.

8. Skerritt U, Evans R, Montgomery SA. Serotonin reuptake inhibitors in old patients. A torelability respective. Drugs Aging. 1997. 10:209–218.

9. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003. 27:85–102.

10. Bourgeois JA, Babine SE, Bahadur N. Case of SIADH and Hyponatremia Associated With Citalopram. Psychosomatics. 2002. 43:241–242.

11. Pergola PE, Sved AF, Voogt JL, Alper RH. Effect of serotonin on vasopressin release. Neuroendocrinology. 1993. 57:550–558.

12. Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol. 2010. 162:S5–S12.

13. Inaguma D, Kitagawa W, Hayashi H, Kanoh T, Kurata K, Kumon S. Three cases of severe hyponatremia under taking selective serotonin reuptake inhibitor (SSRI). Nihon Jinzo Gakkai Shi. 2000. 42:644–648.

14. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone: 1957. J Am Soc Nephrol. 2001. 12:2860–2870.

15. Twardowschy CA, Bertolucci CB, Gracia CM, Brandão MAS. Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine. Arq Neuropsiquiatr. 2006. 64:142–145.

16. Kazal LA, Hall DL, Miller LG, Noel ML. Fluoxetine-induced SIADH: a geriatric occurrence? J Fam Pract. 1993. 36:341–343.

17. Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry. 1998. 13:12–15.

18. Lee SH, Min SK. A Case with the Syndrome of Inappropriate Antidiuretic Hormone Associated with Sertraline. Korean J Psychopharmacol. 1999. 10:95–98.

19. Jackson C, Carson W, Markowitz J, Mintzer J. SIADH associated with fluoxetine and sertraline therapy. Am J Psychiatry. 1995. 152:809–810.

20. Bouman WP, Johnson H, Trescoli-serrano C, Jones RG. Recurrent hyponatremia associated with sertraline and lofepramine. Am J Psychiatry. 1997. 154:580.